Skip to main content

Advertisement

SpringerLink
Log in

Visual evoked potential changes following Botox administration in patients with blepharospasm

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To examine visual evoked potential (VEP) changes following botulinum toxin type A (BTA) administration in patients with blepharospasm.

Methods

Patients diagnosed with blepharospasm receiving BTA administration were included in the study. Three groups, a control group and two study groups (patients examined 14 days after BTA administration—Study Group 1, and patients examined 28 days after BTA administration—Study Group 2) were evaluated. Dilated fundus examinations were performed following detailed ophthalmological examinations and VEP tests. Keypoint (Dantec, Denmark) and ISCEV criteria were adopted for pattern VEP (PVEP) recording. BTA was applied in the form of local injections at a total 15–30 units, at 2.5–5 units per injection.

Results

A mean 19.4 ± 3.2 units of BTA was used for each eye. N70 (ms), P100 (ms), and P100 (uV) values were statistically significantly lower in both study groups following drug administrations compared to the control group (p < 0.001 for all). Significant positive correlation was observed between increased P100 amplitudes and age in the control group (p = 0.008, r = 0.200). Significant negative correlation was observed between the BTA units used and decreased P100 amplitudes in both study groups 1 and 2 following drug administrations (p = 0.017, r = − 0.180 and p = 0.043, r = − 0.153, respectively).

Conclusion

VEP may be an important method in the diagnosis and follow-up of blepharospasm and in determining the success of drug administration and additional therapeutic requirements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barbosa ER, Silva HC, Haddad MS et al (1996) Blepharospasm: treatment with botulinum toxin. Rev Hosp Clin Fac Med Sao Paulo 51:220–223

    CAS  PubMed  Google Scholar 

  2. Papapetropoulos S, Singer C (2007) Botulinum toxin in movement disorders. Semin Neurol 27:183–194

    Article  PubMed  Google Scholar 

  3. Lee JM, Baek JS, Choi HS et al (2018) Clinical features of benign essential blepharospasm in Korean patients. Korean J Ophthalmol 32:339–343

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cossu G, Mereu A, Deriu M et al (2006) Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord 21:2005–2008

    Article  PubMed  Google Scholar 

  5. Nutt JG, Muenter MD, Aronson A et al (1988) Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194

    Article  CAS  PubMed  Google Scholar 

  6. Grandas F, Elston J, Quinn N et al (1988) Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fantato A, Parulekar M, Elston J (2019) A trial of a mechanical device for the treatment of blepharospasm. Eye (Lond) 33:1803–1808

    Article  PubMed  Google Scholar 

  8. Berardelli A, Curra A (2002) Pathophysiology and treatment of cranial dystonia. Mov Disord 17(Suppl 2):S70-74

    Article  PubMed  Google Scholar 

  9. Mukai Y, Kaji R (2011) Use of botulinum neurotoxin therapy. Brain Nerve 63:775–784

    CAS  PubMed  Google Scholar 

  10. Frevert J (2010) Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D 10:67–73

    Article  PubMed  PubMed Central  Google Scholar 

  11. Jankovic J (1998) Medical therapy and botulinum toxin in dystonia. Adv Neurol 78:169–183

    CAS  PubMed  Google Scholar 

  12. Hassell TJW, Charles D (2020) Treatment of blepharospasm and oromandibular dystonia with botulinum toxins. Toxins (Basel) 12:E269

    Article  Google Scholar 

  13. Berardelli A, Conte A (2021) The use of botulinum toxin for treatment of the dystonias. Handb Exp Pharmacol 263:107–126

    Article  CAS  PubMed  Google Scholar 

  14. Tamcelik N (2011) Ocular electrophysiology, 2011th edn. Turkish Ophthalmological Association Education Publications, Istanbul

    Google Scholar 

  15. Jankovic J, Kenney C, Grafe S et al (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407–413

    Article  PubMed  Google Scholar 

  16. Namiguchi K, Mizoue S, Ohta K et al (2018) Effect of botulinum Toxin A treatment on eyelid pressure in eyes with blepharospasm. Curr Eye Res 43:896–901

    Article  CAS  PubMed  Google Scholar 

  17. Brigell M, Bach M, Barber C et al (1998) Guidelines for calibration of stimulus and recording parameters used in clinical electrophysiology of vision. Calibration Standard Committee of the International Society for Clinical Electrophysiology of Vision (ISCEV). Doc Ophthalmol 95:1–14

    Article  CAS  PubMed  Google Scholar 

  18. Jinnah HA, Factor SA (2015) Diagnosis and treatment of dystonia. Neurol Clin 33:77–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Patel B, Weinstein G (1998) Diagnosis and treatment of blepharspazm. Mosby Press, Louis St. In Nesi FA, Lisman RD, Levien MR

  20. Powers JM (1982) Decongestant-induced blepharospasm and orofacial dystonia. JAMA 247:3244–3245

    Article  CAS  PubMed  Google Scholar 

  21. Jankovic J, Orman J (1984) Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 16:371–376

    CAS  PubMed  Google Scholar 

  22. Colosimo C, Bologna M, Berardelli A (2015) How Do I Examine Blepharospasm? Mov Disord Clin Pract 2:449

    Article  PubMed  PubMed Central  Google Scholar 

  23. Nicoletti AGB, Aoki L, Nahas TR et al (2010) Essential blepharospasm: literature review. Arq Bras Oftalmol 73:469–473

    Article  PubMed  Google Scholar 

  24. Odom JV, Bach M, Barber C et al (2004) Visual evoked potentials standard (2004). Doc Ophthalmol 108:115–123

    Article  PubMed  Google Scholar 

  25. Finsterer J, Stöllberger C, Shinar Y (2002) Cranial nerve lesions and abnormal visually evoked potentials associated with the M694V mutation in familial Mediterranean fever. Clin Rheumatol 21:317–321

    Article  CAS  PubMed  Google Scholar 

  26. Odom JV, Bach M, Brigell M et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1–9

    Article  PubMed  Google Scholar 

  27. Kurysheva NI, Maslova EV, Trubilina AV et al (2018) Pattern visual evoked potentials and their relation to the peripapillary and retrobulbar blood flow in glaucoma. Vestn Oftalmol 134:19–27

    Article  CAS  PubMed  Google Scholar 

  28. Amini Vishteh R, Mirzajani A, Jafarzadehpur E et al (2020) Evaluation of visual evoked potential binocular summation after corneal refractive surgery. Doc Ophthalmol 140:181–188

    Article  PubMed  Google Scholar 

  29. Lavinsky J, Gus PI, Ehlers JA et al (2000) Visual-evoked potentials: assessment of retrobulbar and peribulbar anesthesia. J Cataract Refract Surg 26:1529–1532

    Article  CAS  PubMed  Google Scholar 

  30. Alimgil ML, Benian Ö, Esgin H (2001) Tiroid Orbitopatide Oküler Nabız Genliği. Görme Alanı ve Vep MNO 8:414–416

    Google Scholar 

  31. Clauser LC, Tieghi R, Galie’ M et al (2012) Surgical decompression in endocrine orbitopathy. Visual evoked potential evaluation and effect on the optic nerve. J Craniomaxillofac Surg 40:621–625

    Article  PubMed  Google Scholar 

  32. Egan RA, LaFrance WC (2015) Functional vision disorder. Semin Neurol 35:557–563

    Article  PubMed  Google Scholar 

  33. Suzuki Y, Kiyosawa M, Wakakura M et al (2019) Glucose hypometabolism in the visual cortex proportional to disease severity in patients with essential blepharospasm. Neuroimage Clin 24:101995

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Private Neon Hospital, Erzincan, Turkey

    Mehmet Tahir Eski

  2. Department of Ophthalmology, Duzce University Medical School, Duzce, Turkey

    Kuddusi Teberik & Taha Sezer

  3. Department of Neurology, Duzce Ataturk Community Hospital, Duzce, Turkey

    Aziz Hudai Ayasli

  4. Department of Neurology, Istanbul (Duzce University), Liv Hospital Vadi, Istanbul, Turkey

    Ayhan Ozturk

Authors
  1. Mehmet Tahir Eski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kuddusi Teberik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taha Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aziz Hudai Ayasli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ayhan Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

"Dr. Eski wrote the main manuscript text and Dr. Teberik prepared tables 1-3. All authors reviewed the manuscript."

Corresponding author

Correspondence to Mehmet Tahir Eski.

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee (Duzce University Faculty of Medicine) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individuals participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eski, M.T., Teberik, K., Sezer, T. et al. Visual evoked potential changes following Botox administration in patients with blepharospasm. Int Ophthalmol 43, 2101–2107 (2023). https://doi.org/10.1007/s10792-023-02639-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-023-02639-9

Keywords

Search

Navigation